X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced todayPivotal Phase 3 trial of mavorixafor in ...
Business Insider6h
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
Neutrophils are retained in the bone marrow by the CXCR4/CXCL12 axis, creating a reserve of cells. Downregulation of the CXCR4 receptor by mavorixafor, an orally active CXCR4 antagonist, has been ...
Custom icon shapes might return to Pixel phones with Android 16
Google's Android 15 QPR2 Beta 1 reveals the possible return of custom icon shapes for Pixel phones, but with some limits ...